The prevention or correction of hypoglycemia is the result of both dissipation of insulin and activation of counterregulatory systems. In the models studied to date, glucagon and epinephrine have been shown to be the key counterregulatory factors; the potential roles of other hormones, neural factors, or substrate mechanisms in other models and during more gradual recovery from hypoglycemia remain to be defined. Deficient glucagon responses to decrements in plasma glucose, which are common in patients with IDDM and occur in some patients with NIDDM, result in altered counterregulation. But counterregulation is generally adequate, because epinephrine compensates for it. Defective glucose counterregulation due to combined deficiencies of glucagon and epinephrine secretory responses occurs in many patients, typically those with longstanding diabetes, and must be added to the list of factors known to increase the risk of hypoglycemia, at least during intensive therapy. From the material reviewed, it should be apparent that much has been learned about glucose counterregulation. It should be equally clear that much remains to be learned. Among the many possibilities, we consider four worthy of emphasis. First of all, we need to examine the physiology and pathophysiology of glucose counterregulation in additional models (e.g., during exercise) and over longer periods. Secondly, we need to determine whether central nervous system adaptation to antecedent glycemia occurs and, if so, identify its mechanisms. Thirdly, we need to develop better methods of insulin delivery or learn to correct or compensate for defective counterregulatory systems, if we are to achieve euglycemia safely in diabetic patients with defective glucose counterregulation. Finally, we need to know whether effective control of diabetes mellitus prevents development of defective glucose counterregulation.
This article has been cited by other articles:
Cox, D. J., Gonder-Frederick, L., Ritterband, L., Clarke, W., Kovatchev, B. P.
(2007). Prediction of Severe Hypoglycemia. Diabetes Care
30: 1370-1373
[Abstract][Full Text]
Bernroider, E., Brehm, A., Krssak, M., Anderwald, C., Trajanoski, Z., Cline, G., Shulman, G. I., Roden, M.
(2005). The Role of Intramyocellular Lipids during Hypoglycemia in Patients with Intensively Treated Type 1 Diabetes. J. Clin. Endocrinol. Metab.
90: 5559-5565
[Abstract][Full Text]
Aftab Guy, D., Sandoval, D., Richardson, M. A., Tate, D., Davis, S. N.
(2005). Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes. Am. J. Physiol. Endocrinol. Metab.
289: E258-E265
[Abstract][Full Text]
Enoksson, S., Caprio, S. K., Rife, F., Shulman, G. I., Tamborlane, W. V., Sherwin, R. S.
(2003). Defective Activation of Skeletal Muscle and Adipose Tissue Lipolysis in Type 1 Diabetes Mellitus during Hypoglycemia. J. Clin. Endocrinol. Metab.
88: 1503-1511
[Abstract][Full Text]
Oltmanns, K. M., Fruehwald-Schultes, B., Kern, W., Born, J., Fehm, H. L., Peters, A.
(2001). Hypoglycemia, But Not Insulin, Acutely Decreases LH and T Secretion in Men. J. Clin. Endocrinol. Metab.
86: 4913-4919
[Abstract][Full Text]
Sivitz, W. I., Herlein, J. A., Morgan, D. A., Fink, B. D., Phillips, B. G., Haynes, W. G.
(2001). Effect of Acute and Antecedent Hypoglycemia on Sympathetic Neural Activity and Catecholamine Responsiveness in Normal Rats. Diabetes
50: 1119-1125
[Abstract][Full Text]
Genter, P., Berman, N., Jacob, M., Ipp, E.
(1998). Counterregulatory hormones oscillate during steady-state hypoglycemia. Am. J. Physiol. Endocrinol. Metab.
275: E821-E829
[Abstract][Full Text]
Strowig, S. M.
(1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator
19: 50-58
Albisser, A. M., Sperlich, M.
(1992). Adjusting Insulins. The Diabetes Educator
18: 211-219
Slama, G., Traynard, P.-Y., Desplanque, N., Pudar, H., Dhunputh, I., Letanoux, M., Bornet, F. R. J., Tchobroutsky, G.
(1990). The Search for an Optimized Treatment of Hypoglycemia: Carbohydrates in Tablets, Solution, or Gel for the Correction of Insulin Reactions. Arch Intern Med
150: 589-593
[Abstract]
Havlin, C. E., Cryer, P. E.
(1988). Hypoglycemia: The Limiting Factor in the Management of Insulin-Dependent Diabetes Mellitus. The Diabetes Educator
14: 407-411
KENNEDY, F. P., GO, V. L. W., CRYER, P. E., BOLLI, G. B., GERICH, J. E.
(1988). Subnormal Pancreatic Polypeptide and Epinephrine Responses to Insulin-Induced Hypoglycemia Identify Patients with Insulin-Dependent Diabetes Mellitus Predisposed to Develop Overt Autonomic Neuropathy. ANN INTERN MED
108: 54-58
[Abstract]
Virkkunen, M., Nuutila, A., Goodwin, F. K., Linnoila, M.
(1987). Cerebrospinal Fluid Monoamine Metabolite Levels in Male Arsonists. Arch Gen Psychiatry
44: 241-247
[Abstract]
Cryer, P. E.
(1986). The Metabolic Impact of Autonomic Neuropathy in Insulin-Dependent Diabetes Mellitus. Arch Intern Med
146: 2127-2129
[Abstract]
Liggett, S. B., Cryer, P. E.
(1986). Hypoglycemia in the Critically Ill Patient. J Intensive Care Med
1: 149-155
[Abstract]
Datt, N.
(1973). Insulin Pharmacotherapy. Clin-Alert
11: 260-270
Previous
